Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis

A prospective, randomised and placebo-controlled study of 66 children, aged 6–36 months, who were hospitalised due to acute diarrhoea caused by rotavirus.

The children were randomised into three groups: placebo (n=25) or Lactobacillus reuteri ATCC 55730 in a daily dose of 10^7 (n=20) or 10^10 CFU (n=21) for up to five days. All three groups received standard rehydration therapy.

From the second day of treatment, 30% of the children given the lower Lactobacillus reuteri dose were free from watery diarrhoea, compared to 52% of the children given the higher dose. The difference was significant for the high-dose Lactobacillus reuteri group compared to the control group, in which 20% of the children no longer had watery diarrhoea. The high-dose group also had a significantly shorter period of watery diarrhoea: 1.5 days on average compared to 2.5 days in the control group. For the low Lactobacillus reuteri dose group, the mean duration of watery diarrhoea was 1.9 days.

Fig. 1 Percentage of patients with persisting watery diarrhea in the groups receiving placebo (n=25) and small (n=20) and large (n=21) dosages of Lactobacillus reuteri.

Conclusion: The administration of Lactobacillus reuteri in the dose of 10^10 CFU per day significantly shortened the duration of watery diarrhoea in children hospitalised for treatment of acute diarrhoea. The low dose of 10^7 CFU almost reached significant effect on duration of watery diarrhoea.


Shornikova AV, Casas IA, Mykkänen N, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997;16:1103-1107.